Articles
<![CDATA[Analisa Kadar Glutamat pada Penderita Fibrilasi Atrium dengan Gangguan Fungsi Kognitif ]]>
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Andy, Marfri]]>;
<![CDATA[Rasyid, Hauda El]]>
<![CDATA[ Jurnal Kesehatan Andalas Vol. 9 No. 4 (2020): Online December 2020 ]]>
Publisher : <![CDATA[Faculty of Medicine, Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/jka.v9i4.1571
<![CDATA[Salah satu permasalahan neurologi yang ditemukan pada penderita fibrilasi atrium (FA) adalah gangguan kognitif. Silent Brain Infarction (SBI) diyakini menjadi salah satu mekanisme utama yang mendasari terjadinya gangguan ini. Sudah dilaporkan juga bahwa hipoksia serebri akan menimbulkan peningkatan kadar glutamat ektraseluler sehingga bersifat neurotoksisitas dan menimbulkan kematian sel. Tujuan: Menganalisis kadar serum glutamat pada pasien Fibrilasi Atrial (FA) dengan gangguan kognitif.  Metode: Penelitian dengan disain potong lintang dilakukan di Poliklinik Kardiologi dan Neurologi RS DR M Djamil Padang serta Laboratorium Biomed Fakultas Kedokteran Universitas Andalas. Pemeriksaan kadar glutamat serum dilakukan dengan metode Elisa dan pemeriksaan fungsi kognitif dengan test neuropsikologi Montreal Cognitive Assestment versi Indonesia (MoCA-Ina). Perbedaan kadar glutamat serum pada kelompok FA dengan gangguan kognitif dan kelompok FA tanpa gangguan kognitif diuji dengan t test bila distribusi data normal dan test Mann Whitney bila data tidak terdistribusi normal. Hubungan antara kadar glutamat dengan kejadian gangguan kognitif dilakukan dengan uji Chi-square, setelah dicari dulu nilai cut off point untuk kadar glutamat serum. Uji dikatakan bermakna bila nilai p < 0,05. Hasil: Kadar glutamat serum kelompok FA dengan ganggan kognitif lebih tinggi dari kelompok FA tanpa gangguan kognitif. Pasien FA yang mempunyai kadar glutamat tinggi ( > 29,5µMol/L) beresiko mengalami gangguan kognitif 10,2 kali lebih tinggi dari penderita yang mempunyai kadar glutamat normal (< 29,5 µMol). Simpulan: Ada hubungan antara kadar glutamat serum dengan terjadinya gangguan kognitif pada penderita FA.Kata kunci: fibrilasi atrial, fungsi kognitif, glutamat, silent brain infarction]]>
<![CDATA[Gambaran Gejala Depresi pada Penderita Parkinson Disease di RSI Ibnu Sina Padang ]]>
<![CDATA[Mubarak, M. Dzaky]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Nurhayati, Nurhayati]]>;
<![CDATA[Liza, Rini Gusya]]>;
<![CDATA[Syahrul, Muhammad Zulfadli]]>
<![CDATA[ Jurnal Ilmu Kesehatan Indonesia Vol. 5 No. 2 (2024): Juni 2024 ]]>
Publisher : <![CDATA[Fakultas Kedokteran, Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/jikesi.v5i2.1153
<![CDATA[Abstrak Latar Belakang: Penyakit Parkinson merupakan penyakit neurodegeneratif kronik progresif yang ditandai dengan hilangnya sel saraf (neuron) dopaminergik pada bagian substansia nigra. Pada Penyakit Parkinson dapat ditemukan gejala non motorik seperti gejala psikiatri terutama depresi. Depresi pada penderita parkinson memiliki dampak yang sangat besar pada kualitas hidup karena mengakibatkan penurunan kualitas hidup. Objektif: Penelitian ini bertujuan untuk mengetahui karakteristik penderita Penyakit Parkinson, distribusi terjadinya depresi pada parkinson, dan tingkatan depresi yang dialami pada penderita parkinson di RSI Ibnu Sina Padang. Metode: Penelitian ini adalah penelitian deskriptif dengan pendekatan kualitatif metode Cross Sectional dengan kuesioner Beck Depression Inventory. Pengambilan data penelitian berupa data primer dari semua penderita Parkinson yang berobat jalan pada bulan Maret 2023 hingga Mei 2023 di Poli Saraf RSI Ibnu Sina yang memenuhi kriteria dengan jumlah sampel 29 orang. Hasil: Hasil analisis data disajikan dalam bentuk tabel distribusi frekuensi. Hasil penelitian penderita Penyakit Parkinson lebih banyak ditemukan pada kelompok umur lansia dengan jenis kelamin perempuan dan paling banyak sudah tidak bekerja. Sebagian besar masih berstatus kawin dengan lama menderita sakit parkinson mayoritas selama ≥ 5 tahun dan terbanyak didapatkan pada stadium 3 Penyakit Parkinson. Kasimpulan: Mayoritas sebanyak 65,5% mengalami depresi dan paling banyak pada tingkat depresi sedang. Kata kunci: penyakit parkinson; depresi. Abstract Background: Parkinson's Disease is a progressive chronic neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra. In Parkinson's Disease, non-motor symptoms such as psychiatric symptoms, especially depression, can be found. Depression in people with Parkinson's has a very large impact on quality of life because it results in a decrease in quality of life. Objective: This study aims to determine the characteristics of patients with Parkinson's Disease, the distribution of depression in Parkinson's, and the level of depression experienced in patients with Parkinson's at RSI Ibnu Sina Padang. Methods: This research is a descriptive study with a qualitative approach with a cross sectional method using the Beck Depression Inventory questionnaire. Retrieval of research data in the form of primary data from all Parkinson's patients who were on outpatient treatment from March 2023 to May 2023 at the Ibnu Sina Hospital who met the criteria with a sample size of 29 people. Result: The results of this study found that people with Parkinson's Disease were mostly elderly age group, female, and most were not working. Most were still married, had suffered from Parkinson's disease for 5 years and more, and most found in stage 3 Parkinson's Disease. Conclusion: The majority as much as 65.5% experienced depression and most were at moderate levels of depression) Keywords: parkinson's disease; depression]]>
<![CDATA[Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain ]]>
<![CDATA[Husni Minanda Fikri]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Lydia Susanti]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v9i6.1319
<![CDATA[Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.]]>
<![CDATA[Chemotherapy-Induced Cognitive Impairment and Neuroaxonal Damage: Investigating the Role of Serum Neurofilament Light Chain ]]>
<![CDATA[Husni Minanda Fikri]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Lydia Susanti]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v9i6.1319
<![CDATA[Background: Chemotherapy-induced cognitive impairment (CICI), colloquially termed "chemobrain," represents a significant challenge for cancer survivors, potentially affecting up to 85% of patients undergoing treatment. Diagnosis often relies on neuropsychological testing and imaging, which may lack sensitivity for early detection or reflect chronic changes. Neurofilament light chain (NfL), a neuronal structural protein released into biofluids upon neuroaxonal damage, emerges as a promising biomarker. This study investigated the relationship between serum NfL levels and the degree of cognitive impairment in patients receiving chemotherapy. Methods: An observational, cross-sectional study was conducted involving 50 cancer patients undergoing chemotherapy at Dr. M. Djamil General Hospital Padang between October and December 2024. Cognitive function was assessed using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina), and depression was screened using the Patient Health Questionnaire-9 (PHQ-9). Serum NfL levels were quantified using an Enzyme-Linked Immunosorbent Assay (ELISA) method. The Kruskal-Wallis test was employed to analyze the relationship between serum NfL levels and cognitive function status (normal, mild impairment, moderate-severe impairment). Results: Cognitive impairment (MoCA-Ina assessed) was identified in 41 (82%) of the 50 participants, with 30 (60%) exhibiting mild and 11 (22%) exhibiting moderate to severe impairment. The median serum NfL level across all subjects was 23.44 pg/ml (range: 13.81-68.71 pg/ml). A statistically significant relationship was observed between serum NfL levels and the presence and severity of cognitive impairment (p = 0.02). Median NfL levels progressively increased from the cognitively normal group (18.49 pg/ml) to the mild impairment group (23.5 pg/ml) and the moderate-severe impairment group (24.5 pg/ml). Post-hoc analysis revealed significant differences in NfL levels between the normal group and both the mild (p=0.03) and moderate-severe (p=0.01) impairment groups. Conclusion: This study demonstrated a significant positive association between serum NfL levels and the presence and severity of cognitive impairment in cancer patients undergoing chemotherapy. These findings support the potential utility of serum NfL as an accessible biomarker for detecting chemotherapy-associated neuroaxonal damage and concomitant cognitive decline.]]>
<![CDATA[CORRELATION BETWEEN NEURON-SPECIFIC ENOLASE (NSE) SERUM LEVEL AND TRAUMATIC BRAIN INJURY SEVERITY ]]>
<![CDATA[Pitra, Dian Ayu Hamama]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Susanti, Rika]]>;
<![CDATA[Rita, Rauza Sukma]]>
<![CDATA[ Nusantara Hasana Journal Vol. 5 No. 1 (2025): Nusantara Hasana Journal, June 2025 ]]>
Publisher : <![CDATA[Yayasan Nusantara Hasana Berdikari ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.59003/nhj.v5i1.1498
<![CDATA[Traumatic brain injuries (TBIs) are a health and socio-economic problem worldwide, both in low- and high-income countries, that affects all age groups. Computed Tomography (CT) is a diagnostic modality that can be used to assess brain damage. However, there are some limitations in the use of CT in TBIs. Therefore, biomarkers are expected to be a solution to identify brain injuries. Neuron-Specific Enolase (NSE) is a more practical and cheaper alternative. It does not require patient mobilization, especially for patients with severe TBIs, to accompany clinical examinations and CT. Methods: A cross-sectional design was used to determine the correlation between Neuron Specific Enolase (NSE) serum levels and the severity of TBIs at RSUP Dr. M. Djamil, Padang. Results: The study found that most patients were 23 men (76.7%), consisting of adults (40.0%). The majority of patients had mild traumatic brain injury (GCS 13-15) in 18 people (60.0%). The cut-off point for serum NSE was 6.6 ng/ml using the ROC curve. There was a negative correlation between serum NSE levels and the severity of TBI (r=-0.211). Conclusion: The correlation of serum NSE levels with the severity of TBI was very weak.]]>
<![CDATA[Gambaran Gangguan Tidur dan Gangguan Nokturnal pada Penderita Penyakit Parkinson di Rumah Sakit Ibnu Sina Padang ]]>
<![CDATA[Ahmad, Baihaqi]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Rahman, Sukri]]>
<![CDATA[ Jurnal Ilmu Kesehatan Indonesia Vol. 5 No. 1 (2024): Maret 2024 ]]>
Publisher : <![CDATA[Fakultas Kedokteran, Universitas Andalas ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.25077/jikesi.v5i1.1158
<![CDATA[Latar Belakang: Penyakit Parkinson (PP) merupakan salah satu penyakit neurodegeneratif yang merupakan penyebab kelainan motorik terbanyak secara global. Selain gejala motorik, terdapat gejala non motorik yang menurunkan kualitas hidup dari penderita PP. Gangguan tidur adalah salah satu gejala non motorik yang paling sering pada penderita PP. Objektif: Mengetahui gambaran gangguan tidur dan gangguan nokturnal pada penderita Penyakit Parkinson di Rumah Sakit Ibnu Sina Padang. Metode: Penelitian ini merupakan penelitian deskriptif dengan desain cross sectional terhadap 29 orang penderita PP yang berobat ke poliklinik saraf Rumah Sakit Ibnu Sina Padang pada bulan Januari 2023 - Maret 2023 dengan menggunakan teknik total sampling. Gangguan tidur dan gangguan nokturnal subjek dinilai menggunakan kuesioner Parkinson’s Disease Sleep Scale-2 (PDSS-2). Data dianalisis dengan analisis univariat. Hasil: Hasil penelitian ini menunjukkan Kelompok usia terbanyak adalah ≥60 tahun (62,1%). Subjek dengan jenis kelamin perempuan berjumlah 72,4% dan laki-laki 27,6%. Berdasarkan lama sakit subjek semenjak didiagnosis, 75,9% dari subjek telah didiagnosis PP selama ≥5 tahun sedangkan 24,1% telah didiagnosis Parkinson selama <5 tahun. Berdasarkan skala Hoehn dkk., 9 orang (31,1%) subjek sudah berada di stadium 3. Setiap subjek memiliki minimal 1 jenis gangguan tidur atau gangguan nokturnal dengan jenis gangguan yang paling banyak pada subjek adalah nokturia. Kesimpulan: seluruh subjek penelitian memiliki minimal 1 jenis gangguan tidur atau gangguan nokturnal. Jenis gangguan tidur terbanyak diderita oleh subjek adalah Insomnia sedangkan gangguan nokturnal adalah nokturia. Kata kunci: Penyakit Parkinson, Gangguan Tidur, Gangguan Nokturnal, PDSS-2]]>
<![CDATA[Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia ]]>
<![CDATA[Istiqomah]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Fanny Adhy Putri]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v8i9.1060
<![CDATA[Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.]]>
<![CDATA[Plasma pTau181 dan Gejala Neuropsikiatri pada Demensia Alzheimer: Sebuah Studi Cross-Sectional ]]>
<![CDATA[Fadhilah, Nailatul]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Susanti, Restu]]>;
<![CDATA[Indra, Syarif]]>;
<![CDATA[Susanti, Lydia]]>;
<![CDATA[Putri, Fanny Adhy]]>
<![CDATA[ Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025) ]]>
Publisher : <![CDATA[Fakultas Farmasi Universitas Tjut Nyak Dhien ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36490/journal-jps.com.v8i4.1143
<![CDATA[Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.]]>
<![CDATA[Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia ]]>
<![CDATA[Istiqomah]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Fanny Adhy Putri]]>;
<![CDATA[Syarif Indra]]>;
<![CDATA[Restu Susanti]]>;
<![CDATA[Reno Bestari]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v8i9.1060
<![CDATA[Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.]]>
<![CDATA[Serum High Mobility Group Box 1 (HMGB1) Protein Levels and Cognitive Function in Epilepsy Patients: A Cross-Sectional Study ]]>
<![CDATA[Rahmi Ulfa]]>;
<![CDATA[Syafrita, Yuliarni]]>;
<![CDATA[Lydia Susanti]]>
<![CDATA[ Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research ]]>
Publisher : <![CDATA[HM Publisher ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.37275/bsm.v9i2.1183
<![CDATA[Background: Epilepsy is a neurological disease with a high incidence rate. Cognitive decline is one of the consequences of recurrent seizures. Neuroinflammation is closely related to the development of epilepsy and cognitive impairment. An increase in the expression and translocation of High Mobility Group Box 1 (HMGB1) from the nucleus to the extracellular space has been observed in epilepsy patients and experimental animal models. This study aimed to investigate the relationship between serum HMGB1 levels and cognitive function in epilepsy patients. Methods: This cross-sectional observational study involved 45 epilepsy patients. Cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina), and serum HMGB1 levels were measured using the ELISA technique. The relationship between cognitive function and HMGB1 levels was analyzed using the Kruskal-Wallis test, with a significance level set at p < 0.05. Results: The mean age of the participants was 28.5 years, with a higher proportion of females. The mean serum HMGB1 level was 22.6 ng/ml. No significant relationship was found between serum HMGB1 levels and cognitive function in epilepsy patients (p = 0.188). Conclusion: Serum HMGB1 protein levels were not associated with cognitive function in this sample of epilepsy patients.]]>
